TriCelX Press Releases - EIN Presswire - Press Release Distribution Service

Published on April 23, 2026 - 09:00 GMT

TriCelX Receives FDA Study May Proceed Letter for XytriX™

The FDA has issued a Study May Proceed letter for TriCelX's Phase 1/2 IND application for XytriX™, authorizing the commencement of the clinical trial. FRISCO, TX, UNITED STATES, April 23, 2026 /⁨EINPresswire.com⁩/ -- TriCelX, Inc. (“TriCelX”), a …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on March 30, 2026 - 09:00 GMT

TriCelX Files IND with FDA & Concurrently Requests RMAT Designation for XytriX™ in the Treatment of Knee Osteoarthritis

IND Filing and Concurrent RMAT Request Position XytriX™ as a Potential Breakthrough Biotherapeutic for More Than 500 Million People Living with Osteoarthritis THE STAR, FRISCO, TX, UNITED STATES, March 30, 2026 /⁨EINPresswire.com⁩/ -- RMAT DESIGNATION …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on October 22, 2025 - 13:00 GMT

TriCelX, Inc. Announces Opening of TriCelX Utah at the University of Utah Research Park

TriCelX, a global translational leader in evidence-based biologics, announced the opening of its TriCelX Utah location at the University of Utah Research Park. FRISCO, TX, UNITED STATES, October 22, 2025 /⁨EINPresswire.com⁩/ -- TriCelX, Inc. (" …

Distribution channels: Business & Economy, Companies ...